|
|
|
|
|
Selected Publications
Jeong, K-H., Bakowska, J., Song, I.O., Fu, N., Breakefield, X.O. and Kaiser, U.: Improvement in reproductive parameters in hypogonadal female mice by regulated replacement therapy in the central nervous system, Gene Ther., 14:1092-1101, 2007.
Prabhakar, S. Messerli, S.M., Stemmer-Rachmimov, A.O. Liu, T. Rabkin, S. Martuza, R. Breakefield, X.O.: Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47∆. Cancer Gene Ther., 14:460-467, 2007
Hewett, J.W., Tannous, B., Niland, B.P., Nery, F.C., Zeng, J., Li, Y., Breakefield, X.O.: Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proc. Natl. Acad. Sci. U S A 104: 7271-7276, 2007.
Balcioglu, A., Kim, M-O., Sharma, N., Cha, J-H., Breakefield, X.O., Standaert, D.G.: Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem, in press.
Oehmig, A., Cortes, M.L., Perry, K.F., Sena-Esteves, M., Fraefel, C., Breakefield, X.O.: Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector, Gene Therapy, 14:1078-1091, 2007.
Badr, C., Hewett, J., Breakefield, X.O., Tannous, B.: A highly sensitive assay for monitoring of protein secretion and ER stress. PLOS, in press.Hewett, J.W., Zeng, J., Niland, B.P., Bragg, D.C., Breakefield, X.O.: Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. Neurobiol. Dis. 22:98-111, 2006.
Messerli SM, Prabhakar S, Tang Y, Mahmood U, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO: Treatment of schwannomas with an oncolytic HSV recombinant virus in murine models of neurofibromatosis type 2. Hum. Gene Ther. 17:20-30, 2006.
Vasudevan, A., Breakefield, X.O., Bhide, P.: Developmental patterns of torsinA and torsinB expression. Brain Res., 1073-1074:139-145, 2006.
Klein, C., Ozelius, L.J., Breakefield, X.O.: Genetic evaluation in primary dystonia. In Handbook of Dystonia, Ed. M. Stacy, Taylor and Francis Group, New York, 21-44, 2007.
McKee, T.D., Grandi, P., Mok, W., Alexandrakis, G., Insin, N., Zimmer, J.P., Bawendi, M.G., Boucher, Y., Breakefield, X.O. and Jain, R.: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66:2509-2513, 2006.
Kock, N., Naismith, T.V., Boston, H.E., Ozelius, L.J., Corey, D.P., Breakefield, X.O., Hanson, P.I.: Effects of genetic variations in the dystonia protein torsinA: identification of polymorphism at residue 216 as protein modifier. Hum. Mol. Genet., 15:1355-1364, 2006.
Tannous, B.A., Grimm, J., Perry, K.F., Chen, J.W., Weisselder, R., and Breakefield, X.O.: Metabolic biotinylation of cell surface receptors for in vivo imaging. Nature Methods, 3:391-396, 2006.
Cortes, M.L., Oehimg, K.F., Perry, K. F., Sanford, J. and Breakefield, X.O.: Expression of human ATM cDNA in Atm-deficient mouse brain mediated by HSV-1 amplicon vector. Neuroscience, 141:1247-1256. 2006.
Shah, K., Bureau, E., Kim, D.E. Yang, K., Tang, Y., Weissleder, R., Breakefield, X.O.: Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Annals Neurol. 57: 34-41, 2005.
Tannous, B.A., Kim, D.E., Fernandez, J., Weissleder, R., Breakefield, X.O.: Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol. Ther. 11: 435-443, 2005.
Shah, K., Tung, C.H., Breakefield, X.O., Weissleder, R.: In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis, Mol. Ther. 11: 926-931, 2005.
Sharma, N., Baxter, M., Petravicz, J., Bragg, D.C., Schienda, A., Standaert, D., and Breakefield, X.O.: Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. J. Neurosci. 25: 5351-5355, 2005.Shah, K., Jacobs, A., Breakefield, X.O., Weissleder, R.: Molecular imaging of gene therapy for cancer. Gene Ther. 11: 1175-1187, 2004.
Shah, K., Hsich, G., and Breakefield, X.O.: Neural precursor cells and their role in neuro-oncology. Devel. Neurosci. 26: 118-130, 2004.
Naismith, T.V., Heuser, J.E., Breakefield, X.O., Hanson, P.I.: TorsinA in the nuclear envelope. Proc. Natl. Acad. Sci. USA 101: 7612-7617, 2004.
Oehmig, A., Fraefel, C., and Breakefield, X.O.: Update on herpesvirus amplicon vectors. Mol. Ther. 10: 630-643, 2004.
Hewett JW, Kamm C, Boston H, Beauchamp R, Naismith T, Ozelius L, Hanson PI, Breakefield XO, RameshV. TorsinB--perinuclear location and association with torsinA. J Neurochem. 2004 Jun;98(5):1186-94.
Grandi P, Spear M, Breakefield XO, Wang S. Targeting HSV amplicon vectors. Methods. 2004 Jun;33(2):179-86.
Naismith TV, Heuser JE, Breakefield XO, Hanson PI. Torsin A in the nuclear envelope. Proc Natl Acad Aci USA. 2004 May 18;101(20):7612-7. Epub 2004 May 10.
Bagely J, Cortes ML, Breakefield XO, Iacomini J. Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice. Blood. 2004 Jul 15;104(2):572-8. Epub 2004 Mar 25.
Grandi P, Wang S, Schuback D, Krasnykh V, Spear M, Curiel DT, Manservigi R, Breakefield XO. HSV-1 virions engineered for specific binding to cell surface receptors. Mol Ther. 2004 Mar;9(3):419-27.
Bragg DC, Camp SM, Kaufman CA, Wilbur JD, Boston H, Schuback DE, Hanson PI, Sena-Esteves M, Breakefield XO. Perinuclear biogenesis of mutant torsin-A inclusions in cultured cells infected with tetracycline-regulaterd herpes simplex virus tupe 1 amplicon vectors. Neuroscience. 2004;125(3):651-61.
Kamm C, Boston H, Hewett J, Wilber J, Corey DP, Hanson PI, Ramesh V, Breakefield XO. The early onset dystonia protein torsin-A interacts with kinesin light chain 1. J Biol Chem. 2003 May 7;279(19):19882-92. Epub 2004 Feb 17.
Augood SJ, Keller-McGandy CE, Siriani A, Hewett J, Ramesh V, Sapp E, DiFiglia M, Breakefield XO, Standaert DG. Distribution and ultrastructural localization of torsin-A immunoreactivity in the human brain. Brain Res. 2003 Oct 3;986(1-2):12-21.
Bakowska JC, Di Maria MV, Camp SM, Wang Y, Allen PD, Breakefield XO. Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep(+) hybrid amplicon vector. Gene Ther. 2003 Sep;10(19):1691-702.
Cortes ML, Bakkenist CJ, Di Maria, Kastan MB, Breakefield XO. HSV-1 amplicon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Gene Ther. 2003 Aug;10(16):1321-7.
Wang S, Petravicz J, Breakefield XO. Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. Mol Ther. 2003 Jun;7(6):790-800.
Davidson BL, Breakefield XO. Viral vectors for gene deilvery to the nervous system. Nat Rev Neurosci. 2003 May;4(5):353-64/ Review. No abstract available.
Hewett J, Ziefer P, Bergeron D, Naismith T, Boston H, Slater D, Wilbur J, Schuback D, Kamm C, Smith N, Camp S, Ozelius LJ, Ramesh V, Hanson PI, Breakefield XO. Torsin-A in PC12 cells:localization in te endoplasmic reticulum and response to stress. J Neurosci Res. 2003 Apr 15;72(2):158-68.
Rostasy K, Augood SJ, Hewett JW, Leung JC, Sasaki H, Ozelius LJ, Ramesh V, Standaert DG, Breakefield XO, Hedreen JC. Torsin-A protein and neuropathology in early onest generalized dystonia with GAG deletion. Neurobiol Dis. 2003 Feb;12(1):11-24.
Spear MA, Schuback D, Miyata K, Grandi P, Sun F, Yoo L, Nguyen, A, Brandt CR, Breakefield XO. HSV-1 amplicon peptide display vector. J Virol Methods. 2003 Jan;107(1):71-9.
McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, Ueda K, Breakefield XO, Hyman BT. Torsin-A and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem. 2002 Nov;83(4):846-54.
Messerli SM, Tang Y, Giovannini M, Bronson R, Weissleder R, Breakefield XO. Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia. 2002 Nov-Dec;4(6):501-9.
Sena-Esteves M, Hampl JA, Camp SM, Breakefield XO. Generation of Stable retrovirus packaging cell lines after transfection with herpes simplex virus hybrid amplicon vectors. J Gene Med. 2002 May-Jun;4(3):229-39.
Breakefield XO, Kamm C, Hanson PI. Torsin-A: movement at many levels. Neuron. 2001 Jul 19;31(1):9-12. Review.
Lam PY, Breakefield XO. Potential of gene therapy for brain tumors. Hum Mol Genet. 2001 Apr;10(7):777-87. Review.
Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA. 2000 Nov 7;97(23):12846-51. Erratum in: Proc Natl Acad Sci USA 2001 Jan 16;98(2):777.
Schellingerhout D, Rainov NG, Breakefield XO, Weissleder R. Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Ther. 2000 Oct;7(19):1648-55.
Herrlinger U, Woiciechowski C, Sena-Esteves M, Aboody KS, Jacobs AH, Rainov NG, Snyder EY, Breakefield OX. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther. 2000 Apr;1(4):347-57.
Jacobs A, Breakefield XO, Fraefel C. HSV-1 based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systmers and applications. Neoplasia. 1999 Nov;1(5):402-16. Review.
Jacobs A, Breakefield XO, Fraefel C. HSV-1 based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis. Neoplasia. 1999 Nov;1(5):387-401. Review.